A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

This study is looking for adults between 18 and 80 years old who have had a persistent, stubborn cough for at least a year that hasn't gotten better with other treatments. If you are a woman who can become pregnant, you'll need to use very effective birth control during and shortly after the study.

However, there are some reasons why you might not be able to join. For example, if you currently smoke or vape (or have recently quit), or have a history of heavy smoking, this study might not be suitable for you. We also can't include people with certain lung conditions like severe asthma or long-term bronchitis, or if you've recently had a chest infection.

Other reasons you might not be eligible include a recent cancer diagnosis, a history of drug or alcohol misuse, or certain blood infections like HIV or hepatitis. We also can't include anyone who has previously taken part in a study for this specific medicine, BLU-5937.

If you decide to take part in this study, you'll be involved for about 52 weeks. Over this time, you'll have regular visits to the study clinic where the team will monitor your health and how the treatment is affecting your cough. You'll be given either the new medicine, BLU-5937, or a dummy pill to take, as assigned by chance. The team will carefully explain how and when to take your study medication.

During your visits, assessments will likely include checking your cough frequency, which might involve using a special device or keeping a diary, physical examinations, and possibly blood tests or other evaluations to check your health and safety. There will be initial screening appointments to confirm you meet the study requirements, and follow-up visits throughout the 52 weeks to track your progress and any changes. Everything will be explained in detail before you decide to join.